FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151347057> ?p ?o ?g. }

• W2151347057 endingPage "4302" @default.
• W2151347057 startingPage "4298" @default.
• W2151347057 abstract "We previously reported a benefit for all- trans retinoic acid (ATRA) in both induction and maintenance therapy in patients with acute promyelocytic leukemia (APL). To determine the durability of this benefit and identify important prognostic factors, long-term follow-up of the North American Intergroup APL trial is reported. A total of 350 patients with newly diagnosed APL were randomized to either daunorubicin and cytarabine (DA) or ATRA for induction and then either ATRA maintenance or observation following consolidation chemotherapy. The complete remission (CR) rates were not significantly different between the ATRA and DA groups (70% and 73%, respectively). However, the 5-year disease-free survival (DFS) and overall survival (OS) were longer with ATRA than with DA for induction (69% vs 29% and 69% vs 45%, respectively). Based on both induction and maintenance randomizations, the 5-year DFS was 16% for patients randomized to DA and observation, 47% for DA and ATRA, 55% for ATRA and observation, and 74% for ATRA and ATRA. There was no advantage of either induction regimen among any subgroups when CR alone was considered. However, female sex, classical M3 morphology (vs the microgranular variant [M3v]), and treatment–white blood cell count (WBC) interaction (ATRA/WBC below 2 × 109/L [2000/μL] best, DA/WBC above 2 × 109/L worst) were each significantly associated with improved DFS ( P  < .05). Treatment with ATRA, WBC below 2 × 109/L, and absence of bleeding disorder were each significantly associated with improved OS. Age more than 15 years, female sex, and treatment-morphology interaction (DA/M3v worst, ATRA best regardless of morphology) were each significantly associated with improved DFS based on maintenance randomization. The improvement in outcome with ATRA in APL was maintained with long-term follow-up." @default.
• W2151347057 created "2016-06-24" @default.
• W2151347057 creator A5001124933 @default.
• W2151347057 creator A5006619488 @default.
• W2151347057 creator A5007262193 @default.
• W2151347057 creator A5009333851 @default.
• W2151347057 creator A5009716898 @default.
• W2151347057 creator A5013892260 @default.
• W2151347057 creator A5021092277 @default.
• W2151347057 creator A5056405520 @default.
• W2151347057 creator A5061732223 @default.
• W2151347057 creator A5062108544 @default.
• W2151347057 creator A5066356637 @default.
• W2151347057 creator A5068847117 @default.
• W2151347057 creator A5089619585 @default.
• W2151347057 date "2002-08-15" @default.
• W2151347057 modified "2023-10-15" @default.
• W2151347057 title "All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol" @default.
• W2151347057 cites W120786735 @default.
• W2151347057 cites W1496335924 @default.
• W2151347057 cites W1503457234 @default.
• W2151347057 cites W1515269506 @default.
• W2151347057 cites W1521479021 @default.
• W2151347057 cites W1531493896 @default.
• W2151347057 cites W1555554937 @default.
• W2151347057 cites W1576475831 @default.
• W2151347057 cites W1692919389 @default.
• W2151347057 cites W1790757523 @default.
• W2151347057 cites W1919339218 @default.
• W2151347057 cites W1931018750 @default.
• W2151347057 cites W1931891535 @default.
• W2151347057 cites W1948143034 @default.
• W2151347057 cites W1963757118 @default.
• W2151347057 cites W1976511464 @default.
• W2151347057 cites W1979300931 @default.
• W2151347057 cites W1981082999 @default.
• W2151347057 cites W2022260878 @default.
• W2151347057 cites W2048623936 @default.
• W2151347057 cites W2053450804 @default.
• W2151347057 cites W2055229571 @default.
• W2151347057 cites W2065052687 @default.
• W2151347057 cites W2065109309 @default.
• W2151347057 cites W2082173076 @default.
• W2151347057 cites W2090653702 @default.
• W2151347057 cites W2100309315 @default.
• W2151347057 cites W2120204058 @default.
• W2151347057 cites W2128291738 @default.
• W2151347057 cites W2142423276 @default.
• W2151347057 cites W2144749137 @default.
• W2151347057 cites W2314037093 @default.
• W2151347057 cites W2334200141 @default.
• W2151347057 cites W2396425822 @default.
• W2151347057 cites W2409419195 @default.
• W2151347057 cites W2411582113 @default.
• W2151347057 cites W329015177 @default.
• W2151347057 cites W45100087 @default.
• W2151347057 cites W54619631 @default.
• W2151347057 cites W79968274 @default.
• W2151347057 cites W84941526 @default.
• W2151347057 doi "https://doi.org/10.1182/blood-2002-02-0632" @default.
• W2151347057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12393590" @default.
• W2151347057 hasPublicationYear "2002" @default.
• W2151347057 type Work @default.
• W2151347057 sameAs 2151347057 @default.
• W2151347057 citedByCount "419" @default.
• W2151347057 countsByYear W21513470572012 @default.
• W2151347057 countsByYear W21513470572013 @default.
• W2151347057 countsByYear W21513470572014 @default.
• W2151347057 countsByYear W21513470572015 @default.
• W2151347057 countsByYear W21513470572016 @default.
• W2151347057 countsByYear W21513470572017 @default.
• W2151347057 countsByYear W21513470572018 @default.
• W2151347057 countsByYear W21513470572019 @default.
• W2151347057 countsByYear W21513470572020 @default.
• W2151347057 countsByYear W21513470572021 @default.
• W2151347057 countsByYear W21513470572022 @default.
• W2151347057 countsByYear W21513470572023 @default.
• W2151347057 crossrefType "journal-article" @default.
• W2151347057 hasAuthorship W2151347057A5001124933 @default.
• W2151347057 hasAuthorship W2151347057A5006619488 @default.
• W2151347057 hasAuthorship W2151347057A5007262193 @default.
• W2151347057 hasAuthorship W2151347057A5009333851 @default.
• W2151347057 hasAuthorship W2151347057A5009716898 @default.
• W2151347057 hasAuthorship W2151347057A5013892260 @default.
• W2151347057 hasAuthorship W2151347057A5021092277 @default.
• W2151347057 hasAuthorship W2151347057A5056405520 @default.
• W2151347057 hasAuthorship W2151347057A5061732223 @default.
• W2151347057 hasAuthorship W2151347057A5062108544 @default.
• W2151347057 hasAuthorship W2151347057A5066356637 @default.
• W2151347057 hasAuthorship W2151347057A5068847117 @default.
• W2151347057 hasAuthorship W2151347057A5089619585 @default.
• W2151347057 hasBestOaLocation W21513470571 @default.
• W2151347057 hasConcept C104317684 @default.
• W2151347057 hasConcept C126322002 @default.
• W2151347057 hasConcept C143998085 @default.
• W2151347057 hasConcept C203014093 @default.
• W2151347057 hasConcept C2776601000 @default.
• W2151347057 hasConcept C2778461978 @default.

• next